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Abstract
Hereditary angioedema is a serious medical condition caused by a deficiency of C1-inhibitor. The
condition is the result of a defect in the gene controlling the synthesis of C1-inhibitor, which
regulates the activity of a number of plasma cascade systems. Although the prevalence of hereditary
angioedema is low – between 1:10,000 to 1:50,000 – the condition can result in considerable pain,
debilitation, reduced quality of life, and even death in those afflicted. Hereditary angioedema
presents clinically as cutaneous swelling of the extremities, face, genitals, and trunk, or painful
swelling of the gastrointestinal mucosa. Angioedema of the upper airways is extremely serious and
has resulted in death by asphyxiation.
Subnormal levels of C1-inhibitor are associated with the inappropriate activation of a number of
pathways – including, in particular, the complement and contact systems, and to some extent, the
fibrinolysis and coagulation systems.
Current findings indicate bradykinin, a product of contact system activation, as the primary
mediator of angioedema in patients with C1-inhibitor deficiency. However, other systems may play
a role in bradykinin's rapid and excessive generation by depleting available levels of C1-inhibitor.
There are currently no effective therapies in the United States to treat acute attacks of hereditary
angioedema, and currently available agents used to treat hereditary angioedema prophylactically
are suboptimal. Five new agents are, however, in Phase III development. Three of these agents
replace C1-inhibitor, directly addressing the underlying cause of hereditary angioedema and re-
establishing regulatory control of all pathways and proteases involved in its pathogenesis. These
agents include a nano-filtered C1-inhibitor replacement therapy, a pasteurized C1-inhibitor, and a
recombinant C1-inhibitor isolated from the milk of transgenic rabbits. All C1-inhibitors are being
investigated for acute angioedema attacks; the nano-filtered C1-inhibitor is also being investigated
for prophylaxis of attacks. The other two agents, a kallikrein inhibitor and a bradykinin receptor-2
antagonist, target contact system components that are mediators of vascular permeability. These
mediators are formed by contact system activation as a result of C1-inhibitor consumption.
Review
Hereditary angioedema (HAE) is an autosomal dominant
condition caused by mutations to the gene controlling
C1-inhibitor production. This gene would seem to be rel-
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atively mutable. As many as 25% of new patients have no
family history and presumably represent new mutations.
In addition, over 150 different mutations have been iden-
tified [1-3]. Most of the identified mutations have been
included in a C1-inhibitor gene mutation database [4].
Although the exact prevalence of HAE is unknown, it has
been estimated that the condition affects between 1 in
10,000 to 1 in 100,000 individuals [5-7]. HAE was first
clinically described by Heinrich Quincke, in 1882. Vir-
ginia Donaldson and colleagues, about 75 years later,
identified the biochemical defect leading to HAE as sub-
normal or ineffective levels of C1-inhibitor. C1-inhibitor
regulates the activity of the first component of the comple-
ment system, C1-esterase, controlling both C1's rate of
activation, as well as deactivating activated C1. C1-inhib-
itor is also able to inactivate a number of other proteases
in other plasma cascade systems [1,3,8].
Specific mutations have resulted in two main types of
HAE. Type 1 (accounting for approximately 85% of HAE
patients) is characterized by subnormal levels of circulat-
ing
C1-inhibitor. Given the heterozygous nature of the condi-
tion, it might be presumed that plasma levels of C1-inhib-
itor in individuals with the mutation would be 50% of
normal. In fact, levels are typically much lower – between
5% and 30% [2,3]. These low levels suggest enhanced
depletion of C1-inhibitor – the rate of consumption
exceeding the rate of ongoing synthesis – in patients with
the genetic defect, even during asymptomatic periods [9].
In Type 2 HAE (approximately 15% of patients), C1-
inhibitor plasma levels are normal or elevated. High con-
centrations of the mutant protein are typically present due
to the increased half-life of the dysfunctional C1-inhibi-
tor, which fails to form inhibitor-protease complexes. Dif-
ferences in disease severity, manifestation, or clinical
course have not been associated with HAE type, but both
types are associated with a deficiency in functional C1-
inhibitor [2,3].
Clinical Presentation
Increased levels of vascular permeability factors associated
with C1-inhibitor deficiency may result in sudden local
diminishments of endothelial barrier function. Plasma
may then leak from capillaries deeper into cutaneous or
mucosal tissue layers [1,8]. HAE-associated swelling typi-
cally occurs in the facial area and extremities, the upper
airways, the genitourinary tract, and in the gastrointestinal
mucosa. Far less frequent though also reported are epi-
sodes involving the soft palate, the tongue, urinary blad-
der, chest, muscles, joints, kidneys, and the esophagus
[10]. Cutaneous edema is debilitating, may be painful,
and can severely affect quality of life. Abdominal
angioedema can be extremely painful, severe enough to
cause gastrointestinal tract obstruction, and is often
accompanied by diarrhea and/or vomiting [1,2,8,11]. In a
retrospective assessment of 33,671 abdominal
angioedema attacks in 153 patients, Bork and colleagues
reported a mean maximal pain score of 8.4 (range 1–10).
Vomiting accompanied 71% of the attacks, and diarrhea
41%. Circulatory collapse and loss of consciousness were
also described [12]. Abdominal angioedema is often mis-
taken for a surgical emergency; as many as 1/3 of patients
with undiagnosed HAE have undergone exploratory
laparotomy or appendectomy during abdominal attacks
[13].
The most serious form of HAE affects the upper airways
and involves swelling of the larynx and pharynx. Prior to
the development of effective diagnostic techniques and
acute care interventions (where they are available) as
many as 40% of patients with HAE died from an episode
of laryngeal edema. Bork and associates have also
reported a mortality rate as high as 50% associated with
laryngeal edema in patients with undiagnosed HAE
[14,15]. Frequency of attacks and age of onset may show
considerable variation, and the pattern of attacks may
change with age. Attacks typically involve a single site,
though simultaneous attacks at multiple sites are not
uncommon [1].
C1-inhibitor
C1-inhibitor is a protein whose biological function is to
inhibit a number of other proteases involved in the
response to infection, injury, or inflammation. C1-inhib-
itor is the primary regulator of contact and complement
system activation, and may play a minor role in the regu-
lation of coagulation and fibrinolysis [2,3,16,17]. Inap-
propriate activation of these plasma pathways,
particularly of the complement and contact systems, as a
result of C1-inhibitor deficiency, is a central component
in the pathophysiology of HAE [1,2,8,18,19]. C1-inhibi-
tor inactivates C1r and C1s, the serine protease subcom-
ponents of the first component of the complement
pathway [20]. C1-inhibitor also may play a minor role in
the regulation of the coagulation cascade by means of its
inhibitory effects on factor XIIa and factor XIa, as well as
on thrombin formation [1,2,18,20,21]. In the fibrinolytic
pathway, C1-inhibitor participates in the inactivation of
plasmin and tissue plasminogen activator (tPA). How-
ever, under normal physiologic conditions, C1-inhibitor
is not an important inhibitor of either of these proteases
[1,2,19,20,22]. In the contact system pathway, C1-inhibi-
tor inactivates both factor XIIa and active kallikrein,
thereby preventing both the activation of kallikrein from
prekallikrein and the formation of bradykinin, a vascular
permeability factor [2,20,21,23-25]. Given its regulatory
effects on kallikrein, C1-inhibtor might well have been
designated "kallikrein inhibitor."Clinical and Molecular Allergy 2008, 6:2 http://www.clinicalmolecularallergy.com/content/6/1/2
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Mediators of Vascular Permeability
Although C1-inhibitor deficiency has been known to be
the underlying cause of HAE for more than 40 years, the
actual mediator(s) of the vascular permeability character-
istic of the disease remains the subject of continued inves-
tigation. Because the subcutaneous edema associated with
HAE is often painless, and because subcutaneous injec-
tions of bradykinin are acutely painful, investigators ini-
tially believed that a complement-derived permeability
factor would be the most likely mediator of the
angioedema associated with C1-inhibitor deficiency
[2,20]. A complement-derived substance, designated C2
kinin, was initially proposed as a candidate permeability
mediator, but subsequent investigations failed to verify its
activity [26-28].
Bradykinin, a nonapeptide released from kininogen by
kallikrein cleavage, is a downstream product of contact
system activation. It is capable of inducing edema as a
result of its effects on vasodilation and microvessel per-
meability [29]. In vivo investigations demonstrated rapid
elevations in bradykinin in C1-inhibitor-deficient
patients during HAE attacks [30,31]. However, the strong
linkage of bradykinin and angioedema attacks does not
preclude involvement of other plasma cascade products,
such as plasmin and thrombin, in the initiation and dura-
tion of HAE attacks. Clinical and experimental data have
indicated that thrombin formation in the coagulation
pathway is increased during HAE attacks [18]. Several
lines of evidence suggest that plasmin and the fibrinolytic
pathway may also have some involvement in HAE [2,19].
Pathogenesis of HAE Attacks
The main pathogenic mechanism for the generation of
HAE attacks is depletion and/or consumption of C1-
inhibitor. Clinically, attacks of HAE appear to have a
number of environmental and pathophysiological trig-
gers: eg, prolonged mechanical pressure, trauma, emo-
tional stress, menses, or intercurrent illness, particularly
inflammation [1,8]. Angiotensin converting enzyme
inhibitor therapy may trigger attacks in individuals with
HAE [32]. In persons with a mutation associated with C1-
inhibitor deficiency, angioedema attacks may occur spon-
taneously even in the absence of an overt precipitating fac-
tor. Chronically low levels of C1-inhibitor – ≤ 30% of
normal – suggest the possibility of complement and con-
tact systems activation even during apparently symptom-
free periods, so-called autoactivation of the plasma cas-
cade systems. Any further reductions in available C1-
inhibitor would be associated with development of
angioedema symptoms [2].
Since C1-inhibitor is a primary regulator of a number of
proteases and pathways, the activation of any of these pro-
teases and pathways could also lead to further consump-
tion of C1-inhibitor and the development of HAE
symptoms. Chronic, low-level activation of the comple-
ment pathway could lead to the inappropriate activation
of the contact pathway. Vascular permeability and edema
would result from the rapid and excessive release of brady-
kinin [1,20]. Cugno and colleagues have speculated that
the significant increases in prothrombin fragment F1+2 in
the coagulation pathway may involve increased plasma
levels of factor XII, an initiator of the contact pathway that
is activated during HAE attacks [18]. In addition, factor
XIIa and plasmin may serve to activate C1 in the comple-
ment pathway, while factor XIIa or kallikrein in the con-
tact pathway may generate plasmin from plasminogen in
the fibrinolytic pathway [20].
While it may be that only the contact system and bradyki-
nin are directly implicated in the release of vascular per-
meability mediators and angioedema, activation of other
plasma systems, particularly the complement system, may
contribute to the genesis, severity, and duration of the
attack by contributing to the consumption of C1-inhibi-
tor. Activation of these other pathways may also contrib-
ute proteases and factors that could play a role in HAE
attacks. These processes result in a sequence of C1-inhibi-
tor consumption, complement activation, and release of
bradykinin during every acute attack until appropriate
therapy is administered to raise serum levels of C1-inhib-
itor, or until remission spontaneously occurs [1,8].
Therapies for the Management of HAE
Since no effective therapies for acute HAE attacks are avail-
able in the United States, treatment is suboptimal, and
may often result in significant medical, emotional, and
economic consequences. Frequent hospitalizations and
surgical procedures have been associated with this condi-
tion, particularly in untreated or inadequately treated
patients. In the case of life-threatening laryngeal
angioedema, intubation and tracheotomy have been indi-
cated. Inaccurate diagnosis of HAE has resulted in unnec-
essary surgeries and other medical procedures [1,8,10,32].
As with acute therapy, currently available HAE prophylac-
tic treatment options in the U.S. are suboptimal. Attenu-
ated androgens, particularly danazol and stanozolol, have
been used for decades, with good efficacy – while these
agents do not prevent all attacks, they do reduce the
number. Long-term use of these agents, however, is asso-
ciated with substantial risk of side effects and adverse
events, including weight gain, viralization and menstrual
irregularities in women, and dyslipidemia [1,8,33-36].
Szeplaki and colleagues, who found long-term danazol
therapy to be associated with the development of unfavo-
rable lipid profiles, concluded that long-term danazol
prophylaxis should be considered a significant risk factor
for atherosclerosis in patients with HAE, a risk that wouldClinical and Molecular Allergy 2008, 6:2 http://www.clinicalmolecularallergy.com/content/6/1/2
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be compounded in patients also experiencing blood pres-
sure elevations as a result of danazol therapy [36].
In a long-term assessment of HAE prophylaxis with atten-
uated androgens (median treatment time:125.5 months),
Cicardi and colleagues noted an apparent association
between androgen therapy and incidence of arterial
hypertension. While only a single untreated patient (3%)
developed hypertension during the study period, nine
danazol-treated patients (25%; age range, 35 to 74 years,
median age 60) developed hypertension – in some cases
within a few months of therapy initiation [33]. Hyperten-
sion was also found to be a significant adverse event in a
long-term study of danazol prophylaxis in women with
HAE (mean age 35.2 years, mean duration of therapy 60
months). In this study 10% of patients (6/60) developed
hypertension [37]. Salt and water retention associated
with danazol therapy may explain both the weight gain
and hypertension observed in some patients.
Long-term administration of attenuated androgens has
been associated with a number of liver disorders, includ-
ing hepatic cell necrosis and cholestasis [1,38,39]. There
have been case reports of a number of instances of hepa-
totoxicity associated with long-term danazol therapy,
including hepatocellular adenoma and hepatocellular car-
cinoma. Bork and colleagues have described four cases of
hepatocellular adenoma associated with long-term (> 10
yrs) danazol prophylaxis for HAE [40,41]. Several cases of
hepatocellular carcinoma associated with long-term dan-
azol therapy have also been reported, although in these
instances the patients were not being treated for HAE (ie,
a female patient with systemic lupus erythematosus
treated for 4 years with danazol; and a female patient with
idiopathic thrombocytopenia purpura refractory to corti-
cotherapy, intravenous immunoglobulins, vincristine,
and splenectomy, treated with 600 mg danazol daily for 5
years) [42,43].
It is also of concern that the prevalence and severity of
adverse effects associated with attenuated androgens
appear to increase with dosage strength and duration of
therapy [36,44,45].
The lack of therapeutic options should soon be remedied.
Five new therapies are in Phase III clinical development: a
kallikrein inhibitor (DX-88), a bradykinin receptor-2
antagonist (Icatibant), and three C1-inhibitor replace-
ment therapies.
Designed by phage display technology, DX-88 is a recom-
binant protein capable of binding to and inhibiting
human kallikrein. It has a plasma half-life of approxi-
mately 70 minutes when administered intravenously (IV)
and 2 hours when administered subcutaneously (SC). It
has been evaluated for safety and efficacy in several trials
at a range of doses (eg, 5, 10, 20, or 40 mg/m2, given intra-
venously). Patients have reported significant symptom
improvement versus placebo. Serious adverse events have
been reported in a small number of patients, including
shortness of breath and throat edema, as well as pro-
longed prothrombin and thrombin in one patient. Four
patients were observed with post-treatment activated par-
tial thromboplastin times considered abnormal by the
investigator [1,46-48].
Icatibant, a bradykinin receptor-2 antagonist is a synthetic
decapeptide with a structure similar to bradykinin; it is a
highly specific antagonist for bradykinin receptor-2, with
a plasma half-life of approximately 2–4 hours [49]. In an
uncontrolled pilot study, 15 patients (with 20 HAE
attacks) were treated with one of five dosage strengths of
Icatibant (three IV doses: 0.4 mg/kg body weight admin-
istered IV over a period of 2 h; 0.4 mg/kg administered
over a period of 0.5 h; 0.8 mg/kg administered over a
period of 0.5 h; or two SC doses: 30 mg SC; 45 mg SC).
Compared with untreated attacks, Icatibant reduced the
mean time to onset of symptom relief by 97%, from 42 ±
14 hours to 1.16 ± 0.95 hours for all dosage groups. How-
ever, relapse might be an issue. Four patients experienced
five attacks subsequent to treatment (between 14 hours
and 27 hours). The 5 attacks were successfully treated with
rescue C1-inhibitor (Berinert P (1000 U or 500 U). All
patients in whom attacks recurred showed initial response
to Icatibant, including symptom relief [49].
Three C1-inhibitor replacement products are also in Phase
III development: a pasteurized C1-inhibitor, Berinert P,
with a plasma half-life of between 32 and 47 hours [50];
a recombinant human C1-inhibitor isolated from the
milk of transgenic rabbits, rhC1INH (Rhucin), with a
plasma half-life of ~3 hours [1,51]; and a nano-filtered
C1-inhibitor, Cinryze (pharmacodynamics/pharmacoki-
netic data not yet available; Cetor, a comparable agent
though lacking the nano-filtration process in its prepara-
tion, has a half-life of 48 ± 10 hours)[52]. Nano-filtration
is a purification process that has a number of efficient and
robust steps for both virus inactivation or removal and
prion removal [53]. C1-inhibitor replacement therapy not
only suppresses bradykinin release by inactivation of fac-
tor XIIa and kallikrein, but also suppresses activation of
the complement system and perhaps of the fibrinolytic
and coagulation pathways. Although unproven, it is pos-
sible that ongoing activation of these pathways indirectly
contributes to the contact system activation via two mech-
anisms. First, activation of proteases susceptible to inacti-
vation by C1-inhibitor would result in depletion of C1-
inhibitor. Complement system activation, in particular,
would deplete C1-inhibitor because C1r and C1s are
present in greater quantities than most of the other pro-Clinical and Molecular Allergy 2008, 6:2 http://www.clinicalmolecularallergy.com/content/6/1/2
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teases and because complement activation in HAE tends
to be extensive. Secondly, a number of in vitro experi-
ments have suggested, as described previously, that there
may be interactions among the contact, complement and
fibrinolytic systems in which a protease in one system
directly activates a protease in one or both of the other sys-
tems. If such interactions take place in vivo, activation of
one system could eventuate in activation of all three sys-
tems. This would result in release of bradykinin via con-
tact system activation and would further enhance C1-
inhibitor consumption. However, it must be emphasized
that these interactions have not been shown to occur in
vivo.
By inhibiting all of the susceptible proteases of the com-
plement, contact, and fibrinolytic pathways, purified C1-
inhibitor replacement therapy may turn out to provide
more efficient control of angioedema symptoms. How-
ever, this assumption remains to be proven. A related
issue is the observation that some patients, following
treatment, develop recurrent attacks of angioedema after
24 – 48 hours. It is possible that these recurrent attacks are
a function of the half-life of the therapeutic agent or they
could be related to the absence of inhibition of all the pro-
teases susceptible to C1-inhibitor. Long-term recovery
from an attack presumably requires the stabilization of
levels of C1-inhibitor that are sufficiently high to prevent
a recurrence of significant contact system activation with
resultant bradykinin release. If activation of both the con-
tact and complement systems is suppressed, C1-inhibitor
levels might recover more rapidly and early recurrences
might be suppressed. Because plasma-derived C1-inhibi-
tor has a longer half-life and is a broader spectrum inhib-
itor, it has been assumed that such recurrences occur less
frequently with C1-inhibitor therapy but that assumption
awaits verification.
C1-inhibitor has been available for decades in Europe
where it has compiled considerable clinical efficacy and
safety data. In the United States, Waytes and colleagues
treated 11 patients experiencing a total of 55 HAE attacks
with vapor-heated C1-inhibitor concentrate and 11
patients experiencing 49 HAE attacks with placebo [54].
Nearly all HAE attacks (95%) treated with C1-inhibitor
responded to treatment, with an average symptom
improvement response time of ~55 minutes, compared
with just 12% of placebo-treated attacks (P < 0.001). No
adverse events were associated with C1-inhibitor concen-
trate treatment. As mentioned, three C1-inhibitor prod-
ucts are undergoing or have completed Phase III
development in the U.S.
Where it has been available, C1-inhibitor concentrate
purified from human plasma has also been used effec-
tively as a long-term prophylaxis for HAE attacks [1].
Waytes and colleagues reported > 60% reduction in dis-
ease activity in patients treated prophylactically with C1-
inhibitor. Treatment consisted of 5 infusions of either C1-
inhibitor or placebo every third day over two 17-day peri-
ods separated by at least 3 weeks. The second study period
alternated the treatments. No patient receiving C1-inhibi-
tor concentrate demonstrated objective signs of either
laryngeal or genitourinary edema, whereas 4 of 6 placebo-
treated patients demonstrated evidence of attacks in one
or both of those systems [54].
Additionally, in a small study of patients self-administer-
ing C1-inhibitor concentrate, 12 patients in the prophy-
lactic group (10 patients with hereditary C1-inhibitor
deficiency and 2 patients with acquired C1-inhibitor defi-
ciency; there were also 31 patients in the on-demand
group) experienced an attack rate reduction from a mean
of 4 attacks per month to 0.3 attacks per month. The mean
interval between prophylactic injections was 6.8 ± 1.0
days. The mean follow-up time for these patients was 3.5
years [55]. In the United States, one of the C1-inhibitors
currently in development, the nano-filtered agent, cin-
ryze, is also seeking an indication for prophylaxis in addi-
tion to an indication for acute attack treatment.
Whether or not a patient with HAE requires a prophylaxis
regimen will upon a number of patient selection criteria,
including frequency and severity of attacks, and the site of
attacks. Data concerning the number or percentage of
HAE patients either receiving prophylaxis therapy, or who
might be candidates for prophylaxis, are sparse. In their
review of clinical experience of 235 HAE patients over a
period of 19 years, Agostoni and Cicardi found that 30%
experienced more than 1 attack per month; these patients
were considered candidates for continuous prophylactic
treatment [13]. A Spanish registry study of 444 patients
with HAE found that treating physicians considered
approximately 85% of those patients to be symptomatic.
Of those patients, 63% received long-term prophylaxis,
although the criteria upon which prophylaxis was recom-
mended (by physicians) and accepted (by patients) were
not specified [6]. As stated, the decision to recommend,
and to accept, HAE prophylaxis should be based upon a
number of criteria including symptom severity, side
effects' concerns, risk and impairment, etc. Therapy
should always be individually tailored to meet specific
patient needs and requirements.
Conclusion
Hereditary angioedema is a genetic disorder whose under-
lying cause is a deficiency of C1-inhibitor. Although prev-
alence is relatively low, the disease can result in significant
morbidity and mortality for those afflicted. The goals of
HAE therapy are disease management – ie, preventing
attacks, ideally by re-establishing normal physiology, andClinical and Molecular Allergy 2008, 6:2 http://www.clinicalmolecularallergy.com/content/6/1/2
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improving quality of life; and crisis management – ie,
treating acute attacks with utmost efficacy, rapidity, and
safety. Several new therapies for HAE are in development.
The kallikrein inhibitor and the bradykinin receptor-2
antagonist target biologically active products of contact
pathway dysregulation caused by C1-inhibitor deficiency.
These agents inhibit the release or block the activity of
bradykinin, the primary mediator of vascular permeabil-
ity associated with HAE. They do not address the primary
pathophysiologic cause of HAE – C1-inhibitor deficiency.
Several C1-inhibitor replacement products are in develop-
ment, including a pasteurized product, a transgenic agent,
and a nano-filtered C1-inhibitor concentrate. C1-inhibi-
tor replacement therapy addresses the primary cause of
HAE by replacing C1-inhibitor. C1-inhibitor products
have been available for decades in Europe, where they
have been the treatment of choice for acute attacks. C1-
inhibitor concentrate restores regulatory control over all
pathways and biologically active products that may play a
role, either directly or indirectly, in the pathogenesis of
HAE.
Abbreviations
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